Description

Sunshine Biopharma expands its product line to 69 generic drugs with the launch of Olanzapine and Olanzapine ODT in the Canadian pharmaceutical market, revolutionizing mental health treatment options. The strategic launch of these critical medications aligns with the increasing demand for mental health solutions, with the company planning to introduce 20 additional drugs in 2025. Sunshine Biopharma's commitment to affordable generic medications and innovative treatments positions it as a key player in addressing crucial healthcare needs, particularly in the evolving Canadian pharmaceutical landscape.Sunshine Biopharma Expands to 69 Generic Drugs: Olanzapine Launch Revolutionizes Mental Health Treatment. Sunshine Biopharma (NASDAQ:SBFM) has made